Degradation of distinct forms of multimeric vitronectin by human fibroblasts.
The plasma protein vitronectin is thought to be an important regulator of extravascular plasminogen activation. In previous studies we have shown that a disulfide stabilized multimeric form of vitronectin is endocytosed and degraded by fibroblast cells (T.S. Panetti, P.J. McKeown-Longo, J. Biol. Chem. 268 (1993) 11988-11993; P.J. McKeown-Longo, T.S. Panetti, in: K.T. Preissner, S. Rosenblatt, C. Kost, J. Wegerhoff, D.F. Mosher (Eds.), Biology of Vitronectins and their Receptors, Elsevier Science Publishers, Amsterdam, 1993, pp. 111-118). The preparation of multimeric vitronectin used in these earlier studies was in the form of high molecular weight disulfide-bonded aggregates which were stable in sodium dodecyl sulfate (SDS). To address the question of whether vitronectin needed to be in the form of disulfide stabilized multimers in order to be endocytosed, a multimeric vitronectin, which was not disulfide stabilized, was prepared from vitronectin that had been treated with reducing agent and alkylated with iodoacetamide. The resulting protein migrated as a 65/75 kDa protein on SDS gels in the absence of reducing agent, confirming that this form of vitronectin was no longer stabilized into disulfide-bonded aggregates. However, the protein was still multimeric when analyzed by native gels and could be converted to SDS stable multimers by cross-linking agents. This result demonstrated that reduced and alkylated vitronectin aggregates into multimeric forms which are not stable in SDS. Similar to disulfide stabilized multimers, alkylated multimers of vitronectin bound to sulfated proteoglycans in the extracellular matrix and were endocytosed and degraded. Degradation of both forms of vitronectin was inhibited with arginine-glycine-aspartic acid peptides, an anti-alphavbeta5 antibody and heparin. Chloroquine and wortmannin were also able to inhibit degradation of both forms of vitronectin, indicating that both multimeric forms were following the same endocytic and degradative pathway. These results suggest that the organization of vitronectin into a multimeric form which will be recognized for endocytosis does not require disulfide bond stabilization. This study further suggests that recognition of vitronectin for endocytosis is dependent upon its conversion from a monomeric to a multivalent form (C.E. Wilkins-Port, P.J. McKeown-Longo, Mol. Biol. Cell 8:S:64A (1997).
Wilkins-Port
C E
CE
Cell and Molecular Biology Program and the Department of Physiology and Cell Biology (Mail Code 134), Neil Hellman Medical Research Building, Albany Medical College of Union University, 47 New Scotland Avenue, Albany, NY 12208, USA.
McKeown-Longo
P J
PJ
D000478:Alkylation; D000730:Androstadienes / Q000494:pharmacology; D001205:Ascorbic Acid / Q000494:pharmacology; D002478:Cells, Cultured; D002738:Chloroquine / Q000494:pharmacology; D004705:Endocytosis; D005347:Fibroblasts / Q000378:metabolism*; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D016023:Integrins / Q000378:metabolism; D008247:Lysosomes / Q000378:metabolism; D009842:Oligopeptides / Q000494:pharmacology; D011509:Proteoglycans / Q000378:metabolism; D019030:Receptors, Vitronectin; D019096:Vitronectin / Q000032:analysis / Q000737:chemistry / Q000378:metabolism*; D000077191:Wortmannin
D000730:Androstadienes; D016023:Integrins; D009842:Oligopeptides; D011509:Proteoglycans; D019030:Receptors, Vitronectin; D019096:Vitronectin; C064660:integrin alphaVbeta5; C047981:arginyl-glycyl-aspartic acid; D002738:Chloroquine; D006493:Heparin; D001205:Ascorbic Acid; D000077191:Wortmannin